Objective: The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis. Method: In a 52-week double-blind, multicenter study, 400 patients early in the course of psychotic illness (<5 years) were randomly assigned to treatment with olanzapine (2.5–20 mg/day), quetiapine (100–800 mg/day), or risperidone (0.5–4 mg/day). The mean modal daily dose was 11.7 mg (SD=5.3) for olanzapine, 506 mg (SD=215) for quetiapine, and 2.4 mg (SD=1.0) for risperidone. A total of 224 patients completed neurocognitive assessments at baseline and at 12 weeks, and 81 patients also completed them at 52 weeks. Neurocognitive composite scores were calculated from the neurocognitive battery used in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and from the Brief Assessment of Cognition in Schizophrenia. Results: At week 12, there was significant improvement in neurocognition for each treatment (p<0.01), but no significant overall difference between treatments. Composite z score improvements on the CATIE neurocognitive battery were 0.17 for olanzapine, 0.33 for quetiapine, and 0.32 for risperidone. Composite z score improvements on the Brief Assessment of Cognition in Schizophrenia were 0.19 for olanzapine, 0.34 for quetiapine, and 0.22 for risperidone. Statistically significant relationships between improvements in neurocognition and functional outcome were observed at weeks 12 and 52. Conclusions: Olanzapine, quetiapine, and risperidone all produced significant improvements in neurocognition in early-psychosis patients. Although cognitive improvements were modest, their clinical importance was suggested by relationships with improvements in functional outcome.
In patients with schizophrenia, neurocognitive deficits have been established as an important symptom domain associated with long-term outcome. On average, these patients perform one to two standard deviations below healthy individuals on neurocognitive measures, such as those assessing attention, executive function, memory, and processing speed (1, 2) . These deficits are clearly present at the first episode of illness (3 – 5), even in antipsychotic-naive patients (6, 7), and thus are not a deleterious effect of treatment. These deficits appear to be only marginally corrected with conventional antipsychotic agents in patients early in the course of psychotic illness, even when medication is administered at lower doses (8 – 10) .
Because neurocognitive deficits are among the strongest predictors of functional outcome in patients with schizophrenia (5, 11, 12), interventions that reduce these deficits may be particularly useful; neurocognitive improvement may enhance patients’ recovery and functional life outcomes. However, little research has examined the relationship between cognitive improvement with treatment and functional improvement in patients with psychotic disorders.
Treatment with atypical antipsychotics has been found, in various studies, to produce improvements in neurocognitive performance in schizophrenia (3, 13 – 23 ; see also the meta-analyses in references 20, 24, 25 and early psychosis in references 8 – 10) . However, the comparator medication in many of these studies was a conventional antipsychotic administered at doses large enough to produce substantial extrapyramidal symptoms requiring treatment with anticholinergics, and both of these classes of medication are associated with impaired cognition (20) . In previous studies, antipsychotic-naive patients with early psychosis receiving olanzapine (8, 9) or risperidone (10) demonstrated greater neurocognitive improvement than those receiving haloperidol, even when haloperidol was given in low doses. In this study, we compared the neurocognitive effects of olanzapine and risperidone and a third atypical antipsychotic, quetiapine. Our primary hypothesis was that the three agents would be equivalent in their effects on various neurocognitive measures.
This study is the first head-to-head comparison of the cognitive effects of atypical antipsychotics in early psychosis. In this article, we examine the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients early in the course of psychotic illness and the relationship of cognitive changes to changes in functioning and quality of life. In a companion article in this issue (26), we report results for the primary outcome measure of all-cause treatment discontinuation and secondary measures of psychopathology, quality of life, and side effects.
Method
This was a 52-week randomized, double-blind, flexible-dose, multicenter study of patients early in the course of schizophrenia, schizoaffective disorder, or schizophreniform disorder assigned to treatment with olanzapine, quetiapine, or risperidone.
Study Population
Participants were recruited from inpatient, outpatient, and emergency department services for the evaluation and treatment of psychosis. The study was approved by the institutional review board at each site, and written informed consent was obtained from the patients or their legally authorized representatives. Consenting patients 16–40 years of age were eligible for the study if they met DSM-IV criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. Patients had to be in the first episode of their psychotic illness and had to have been continuously ill for at least 1 month and no more than 60 months. Patients were excluded if a prior psychotic episode had remitted for 3 months or more or if they had prior antipsychotic drug treatment for more than 16 cumulative weeks. Several exceptions to these criteria were allowed on a case-by-case basis: the study included nine patients who had been ill for more than 60 months, seven who were over 40 years of age, and 16 who had taken antipsychotics for more than 16 weeks. All patients had a score ≥4 on at least one psychosis item in the Positive and Negative Syndrome Scale (PANSS; 27) and a score ≥4 (moderately ill) on the severity of illness item of the Clinical Global Impression scale (CGI) at the point of maximum severity of illness to date. Female participants of childbearing potential had to be using a medically acceptable form of contraception.
We excluded patients who did not speak English; had a history of mental retardation; were pregnant or nursing; had a serious, unstable medical illness; had a known allergy to one of the study medications; were at serious risk of suicide; or had participated in an investigational drug trial within 30 days before the first treatment visit.
Study Treatments
Patients were randomly assigned to treatment with olanzapine (2.5–20 mg/day), quetiapine (100–800 mg/day), or risperidone (0.5–4 mg/day). On days 1 and 2, each patient received one capsule of olanzapine (2.5 mg), quetiapine (100 mg), or risperidone (0.5 mg) in the evening. At the treating physician’s discretion, the dose could be increased by one capsule every other day—i.e., on days 3 and 4, one capsule in the morning and one in the evening; on days 5 and 6, one capsule in the morning and two in the evening; and so on, up to a maximum of four capsules twice daily.
Any previous antipsychotic therapy was tapered and discontinued during the first 2 weeks of double-blind treatment, and no subsequent use of an additional antipsychotic was permitted. Treatment with an adjunctive antidepressant or mood stabilizer during the first 8 weeks of treatment was not allowed unless approved by the project medical officer. Anticholinergic medications for acute extrapyramidal side effects were permitted for up to a total of 2 weeks over the course of the trial. Clinicians were encouraged to lower the dose of antipsychotic to relieve extrapyramidal side effects. Otherwise, adjunctive and concomitant medications could be used without restriction. This strategy kept the frequency of use for benzodiazepines, antidepressants, mood stabilizers, and anticholinergics below 5% during the study.
Assessments
The screening evaluation included a diagnostic interview (the Structured Clinical Interview for DSM-IV), medical history, physical examination, measurement of vital signs, and laboratory tests.
Training covering the study protocol and administration of all study evaluations was provided at an investigator meeting. Cognitive testers who could not attend the meeting and raters who joined the study after the investigator meeting participated in the same training using web-based materials, teleconferencing, and phone certification procedures.
Study visits occurred at baseline, at weekly intervals for the first 6 weeks, every other week for the next 6 weeks, and monthly thereafter. Neurocognitive assessments were conducted at baseline (up to 2 weeks after the start of treatment) and at weeks 12 and 52 (up to 2 weeks before or after the target date) or when the patient terminated the study if it was before week 52. A total of 224 patients completed neurocognitive assessments at baseline and 12 weeks, and 81 patients also completed them at 52 weeks. Cognitive testers were not blind to adverse event status and use of concomitant medications.
The primary neurocognitive outcome measure for this study was a composite score derived from the neurocognitive battery used in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The performance of the 1,331 patients assessed at baseline is described in detail elsewhere (28) . For the calculation of the CATIE battery composite score, all test measures were first converted to standardized z scores by setting the sample mean of each measure at baseline to zero and the standard deviation to 1. Summary scores for some tests were calculated by averaging z scores from individual measures: a Wisconsin Card Sorting Test score was calculated by averaging z scores for preservative errors and categories achieved; a Continuous Performance Test score was calculated by averaging the z score of d -prime for the three different Continuous Performance Test conditions; and the Controlled Oral Word Association Test and category instances summary measures were averaged together to form one summary test score referred to as verbal fluency. For domains with more than one test, summary scores were determined by calculating the mean of the z scores for the measures that comprised the domain, then converting the mean to a z score with a mean of zero and a standard deviation of 1. This resulted in nine test summary scores and five domain scores corresponding to five of the seven domains in the Measurement and Treatment Research to Improve Cognition in Schizophrenia consensus battery (29) . A domain-based composite score was defined as the average of the five domain summary scores for the CATIE neurocognitive battery.
An additional neurocognitive outcome measure was the composite score on the Brief Assessment of Cognition in Schizophrenia (BACS; 30, 31), a briefer set of tests designed to derive a composite score. With the BACS, we sought to determine its relative sensitivity to treatment-related cognitive changes compared with the larger CATIE battery; we also wanted to enable comparisons between this study and other trials using the BACS. The BACS, which takes approximately 35 minutes to administer, includes brief assessments of reasoning and problem solving, verbal fluency, processing speed, verbal memory, working memory, and motor functions. The BACS composite score was calculated by summing the z scores for each of the six measures, obtained by comparing each measure with a healthy comparison sample and dividing by the standard deviation of the healthy comparison sample (30) . This composite score has high test-retest reliability in patients with schizophrenia and healthy comparison subjects (intraclass correlation coefficients >0.80) (30) . Pearson correlations between the BACS composite score and CATIE neurocognitive composite score in this study were r=0.84 at baseline, r=0.86 at 12 weeks, and r=0.90 at 53 weeks (all p values <0.001). Table 1 summarizes the neurocognitive domains assessed by the CATIE battery and the BACS.
Severity of psychopathology was measured with the PANSS and the CGI severity item. Functional outcome was measured with the standard patient interview from the Heinrichs-Carpenter Quality of Life Scale (32), emphasizing the vocational and social outcome dimensions.
Statistical Analysis
Analyses of the neurocognitive variables were specified in a statistical analysis plan that was finalized before the blind was broken. Baseline measures of demographic and clinical characteristics were compared using two-sided Kruskal-Wallis tests for continuous variables and Fisher’s exact test for categorical variables. Separate general linear models provided least square means estimates for changes in cognitive scores from baseline to weeks 12 and 52 for each treatment group, adjusting for baseline and weeks of treatment in cases where neurocognitive testing was completed 1 to 2 weeks before or after the scheduled visit. The effect of group membership on neurocognitive change scores was tested using the F statistic from the model, followed by pairwise comparisons between treatment groups if overall treatment effect was significant. Pearson partial correlation coefficients were used to examine the potential linear relationships between treatment-related changes in the neurocognitive composite scores and treatment-related changes in the clinical outcome measures and the social and vocational subscale scores on the Heinrichs-Carpenter Quality of Life Scale from baseline to weeks 12 and 52 in each treatment group and in the cohort as a whole. These correlations were adjusted for baseline cognitive and clinical measures.
The primary analysis tested the overall treatment effect on CATIE neurocognitive battery composite scores from baseline to week 12 at the 0.05 significance level. All subsequent analyses on individual cognitive tests and between treatment groups were intended to expand our major finding and should be considered exploratory. Therefore, no p value adjustments were made for multiple comparisons.
Results
Baseline Characteristics
Table 2 presents demographic and clinical characteristics for the three treatment groups and the whole cohort. There were no significant differences between treatment groups. Patients demonstrated moderate levels of psychopathology at baseline, as reflected in scores on the PANSS, the CGI severity item, and the Calgary Depression Scale for Schizophrenia.
Pharmacological Treatments
The mean modal prescribed daily doses of study drugs were 11.7 mg (SD=5.3) for olanzapine, 506 mg (SD=215) for quetiapine, and 2.4 mg (SD=1.0) for risperidone; the mean modal numbers of prescribed capsules per day were 4.7 (SD=2.1) for olanzapine, 5.1 (SD=2.2) quetiapine, and 4.7 (SD=2.0) for risperidone. Since adjunctive treatments were discouraged, their use was rare after baseline. The use of mood stabilizers, antidepressants, benzodiazepines, and anticholinergics during the study is summarized in Table 3 . There were no significant differences between treatment groups in use of adjunctive medication.
Effects on Neurocognition
At week 12, each of the treatments significantly improved the composite score on the CATIE neurocognitive battery compared with baseline (p<0.01 for olanzapine, p<0.001 for quetiapine and risperidone) ( Table 4 ). There was no significant difference between treatments in the magnitude of cognitive improvement. Mean z score improvements in the CATIE composite score were 0.17 for olanzapine, 0.33 for quetiapine, and 0.32 for risperidone ( Figure 1 ).
Figure 1. Changes in CATIE Neurocognitive Battery Composite Score From Baseline to Weeks 12 and 52 in Patients Treated With Olanzapine, Quetiapine, or Risperidone a
a CATIE=Clinical Antipsychotic Trials of Intervention Effectiveness.
b p<0.01.
c p<0.001.
There was considerable attrition at week 52, with only 81 patients providing enough neurocognitive data for the calculation of the CATIE composite score. The baseline and week 12 cognitive measures of patients who remained in the study until week 52 were not significantly different from those of patients who dropped out of the study. The magnitude of cognitive improvement from baseline to endpoint was similar for patients who stayed through to week 52 (0.09 for olanzapine, 0.24 for quetiapine, and 0.27 for risperidone) ( Figure 1 ), but the within-group treatment effects on CATIE battery composite scores at week 12 were no longer significant at week 52.
Exploratory analyses of individual neurocognitive measures at week 12 suggested differences between treatments on the following tests from the CATIE battery: verbal fluency, letter-number sequencing, WAIS-R digit symbol subtest, and Continuous Performance Test d -prime ( Table 4 ). Subsequent pairwise comparisons of treatment groups showed that at 12 weeks, the improvement in cognition was greater in the quetiapine group than in the olanzapine group (p<0.05) on measures of verbal fluency, the WAIS-R digit symbol subtest, and the Continuous Performance Test d -prime. Compared with the risperidone group at 12 weeks, the improvement in cognition was greater in the quetiapine group (p<0.05) on measures of verbal fluency and the WAIS-R digit symbol subtest. The improvement in cognition was greater in the risperidone group than in the olanzapine group (p<0.05) on letter-number sequencing at 12 weeks. No other pairwise comparisons were significant, and there were no significant differences between treatments for individual neurocognitive measures at week 52.
Relationship Between Cognitive Change and Symptom Change
As reported in the companion article in this issue (26), symptom reduction as rated on the PANSS and the CGI severity item was substantial in each treatment group, ranging from 11.6 to 14.3 points on PANSS total score and 0.8 to 0.9 points on the CGI severity item score at 12 weeks, and 15.6 to 18.5 points on PANSS total score and 1.2 to 1.3 points on the CGI severity score at 52 weeks. Correlations between the CATIE neurocognitive battery composite score and symptom changes at week 12 for the entire study population were small, ranging from –0.18 to –0.26. Within treatment groups, the majority of the 15 correlations between change in CATIE composite score and change in PANSS or CGI severity score at week 12 were in the effect size range of small (r=–0.1) to medium (r=–0.3), with a median correlation of –0.25. The correlations between cognitive change and change in clinical symptoms for the study population at week 52 had a range of –0.26 to –0.44. Correlations between cognitive change and global clinical change within each treatment group were mainly in the range of medium to large (r=–0.5), with a median correlation of –0.33 ( Table 5 ). The correlations between cognitive change and symptom change tended to be larger in the olanzapine group.
Relationship Between Cognitive Change and Change in Functional Outcome
As reported in the companion article (26), changes in the vocational and social subscales of the Heinrichs-Carpenter Quality of Life Scale were small at 12 weeks (less than 0.2 standard deviations) and in the range of medium effects (about 0.5 standard deviations) for each treatment group at 52 weeks. In analyses of the total study population pooled across treatment groups at week 12 (N=219), partial correlations between change in the CATIE neurocognitive battery composite score and change in Heinrichs-Carpenter Quality of Life Scale subscores, controlling for baseline CATIE composite score and PANSS total score, were 0.14 (p=0.04) for vocational outcomes and 0.18 (p=0.009) for occupational outcomes. These partial correlations were slightly larger at week 52 (N=77; r=0.22 [p=0.056] to 0.36 [p=0.001]). Within-treatment correlations between cognitive change and functional change are presented in Figure 2 . Regression analyses conducted to further examine the relationship between cognitive, symptom, and functional change suggested that the variance in social and vocational functioning predicted by the CATIE composite score was not statistically significant when additionally controlled for change in PANSS score during treatment.
Figure 2. Partial Pearson Correlations Between Change in CATIE Neurocognitive Battery Composite Score and Change in Functional Outcome Measures From Baseline to Weeks 12 and 52, Controlling for Baseline CATIE Composite Score and PANSS Total Score a
a CATIE=Clinical Antipsychotic Trials of Intervention Effectiveness; PANSS=Positive and Negative Syndrome Scale
b p<0.01.
Relationship Between Cognitive Change and Changes in Side Effects
Correlations between cognitive change and changes in side effects, as measured by scores at 12 and 52 weeks on the Abnormal Involuntary Movement Scale (33), the Barnes Rating Scale for Drug-Induced Akathisia (34), and the Simpson-Angus Rating Scale (35), were not statistically significant. Use of anticholinergic treatment or presence of sleepiness or akinesia was not significantly related to cognitive performance at 12 or 52 weeks.
Relationship Between CATIE Neurocognitive Battery and BACS
Treatment effects on the BACS composite score were similar to those on the CATIE battery composite score. The BACS data are described in more detailed tables and figures in a data supplement that accompanies the online version of this article. A total of 214 patients completed both the CATIE and BACS batteries at baseline and 12 weeks, and 76 completed both batteries at baseline and 52 weeks. For the entire cohort, change in the CATIE composite score was highly correlated with change in the BACS composite score at 12 weeks (r=0.57, df=212, p<0.001) and at 52 weeks (r=0.70, df=74, p<0.001). The BACS composite score changes were 0.19 for olanzapine (p<0.01), 0.34 for quetiapine (p<0.001), and 0.22 for risperidone (p<0.01), similar to those of the CATIE battery. Between-groups comparisons of individual BACS measures and correlations with symptom and side effect change paralleled the CATIE battery findings, with slightly more (4 of 12) significant relationships with functional outcomes.
Discussion
This is the first randomized, double-blind study comparing the neurocognitive effects of atypical antipsychotic agents in the treatment of patients early in the course of psychotic illness. Olanzapine, quetiapine, and risperidone produced modest but significant improvements in neurocognitive test performance. There were no significant differences between treatments in overall cognitive composite scores, which suggests that quetiapine may provide modest cognitive benefit to patients with early psychosis that is in line with that provided by olanzapine and risperidone. Improvement in the cognitive composite scores was significantly associated with improved social and occupational functioning as measured by the Heinrichs-Carpenter Quality of Life Scale. This result is the first direct evidence that antipsychotic treatment-related cognitive changes in patients with early psychosis may be clinically relevant for occupational and social functioning. However, interpretation of this relationship is tempered by analyses indicating that symptom change and baseline cognitive scores also predicted the variance in functional outcomes. Thus, cognitive improvement may be a part of a general treatment response that is associated with improved functional outcomes.
The magnitude of neurocognitive improvement for olanzapine and risperidone in this study is slightly less than that previously reported in comparisons with conventional antipsychotics in early-psychosis patients (8 – 10) . In earlier studies that used doses similar to those we used in this study (8, 9), the magnitude of the effect of olanzapine on neurocognitive composite scores was 0.36 at 12 weeks and 0.56 at 52 weeks; in this study, olanzapine’s effect was weaker, with effect sizes of 0.17 and 0.09 at 12 and 52 weeks, respectively. The magnitude of the effect of risperidone on neurocognition in an earlier study (10) was 0.4 at 12 weeks, whereas in this study, effect sizes for risperidone were 0.32 and 0.27 at 12 and 52 weeks, respectively.
The reason for the lesser effect of olanzapine and risperidone on neurocognition in this study compared with previous studies is not entirely clear. These differences in magnitude are small and could be due to random factors or to methodological advances in the current study that may have served to refine the estimate of the magnitude of cognitive treatment effects, such as the inclusion of alternate verbal memory tests, which is likely to yield lower estimates of improvement because of repeated test exposure (8 – 10) . Another possible factor is prior exposure to antipsychotics. Patients who are antipsychotic-naive when beginning treatment have been shown to obtain particularly large benefits from treatment with atypical antipsychotics (9) . While about three-quarters of the patients in this study and in the earlier olanzapine study had briefly received treatment with antipsychotics prior to randomization, in this more recent study the medications received previously were more likely to have been atypical antipsychotics, particularly olanzapine or risperidone. Patients who were randomly assigned to the same medication that they were receiving at or before baseline may have had a reduced neurocognitive response to further treatment (36) . Moreover, patients were given a 2-week window after treatment initiation to complete baseline neurocognitive testing. Thus, very early cognitive effects of antipsychotic treatment might have occurred in some of these patients, which may have minimized measurements of cognitive treatment response.
The significant benefit of quetiapine treatment on neurocognitive measures in patients with early psychosis is a new observation. Previous work has suggested that olanzapine (8, 9) and risperidone (10) provide greater cognitive benefit than low doses of haloperidol in patients with early psychosis. Our findings in this study suggest that the effect of quetiapine on cognition may be as beneficial as that of olanzapine or risperidone, and thus this agent may be another evidence-based alternative for clinicians who focus on cognitive outcomes. However, results from a recent study of 240 schizophrenia patients with stable symptoms treated with donepezil or placebo over a 12-week period suggest that the amount of cognitive change we report here is consistent with what may be expected from practice effects and placebo effects (unpublished 2004 study of R. Keefe et al.). This series of results raises the question of whether even low doses of haloperidol have a deleterious impact on cognition and whether the cognitive benefit of atypical antipsychotics derives from their reduced adverse effects rather than procognitive effects. It is noteworthy, however, that this negative effect may not occur with the conventional antipsychotic perphenazine, whose cognitive effects were similar to those of atypical antipsychotics in the CATIE schizophrenia trial (37).
Although much of our results stem from exploratory analyses with a large number of outcome measures not corrected for multiple comparisons, the pattern of results raises the possibility that quetiapine may have particular benefit on tests of verbal fluency and coding, in both the processing speed domain (38) and vigilance. These data support previous findings (16, 19, 22) as well as conclusions from a meta-analysis suggesting that quetiapine has a particularly beneficial impact on verbal fluency and vigilance (24) . Perhaps quetiapine’s lack of appreciable affinity for muscarinic cholinergic receptors (39), which minimizes anticholinergic effects, and its fast dissociation from striatal dopamine D 2 receptors (40), which minimizes potential adverse effects on frontostriatal systems (including reduced thalamocortical drive), allow for more efficient processing speed.
The course of cognitive improvement with atypical antipsychotics is controversial. While some long-term studies have reported increasing cognitive improvement over time (9, 41), others have not (42) . Furthermore, the additional cognitive benefit over time may depend on significant patient attrition (9) . Grouped data from all studies of atypical antipsychotics suggest little additional cognitive benefit beyond the initial gains in the early phases (6–10 weeks) of treatment (unpublished 2004 analysis of R. Keefe and J. Cone). Our findings in this study support this view, as the magnitude of cognitive improvements across all domains was similar at 12 and 52 weeks, suggesting that most of the cognitive benefit of atypical antipsychotics occurs in the first few months of treatment. This finding may be particularly relevant for clinicians deciding whether to keep a patient on an antipsychotic treatment; it suggests that patients who do not demonstrate early cognitive benefit with a particular medication are unlikely to show benefit with continued treatment. After 12 weeks of treatment, all correlations between cognitive improvement and symptom improvement were less than 0.3, which is considered to be a medium effect, and most were closer to 0.1, which is a small effect (43) . Thus, it is unlikely that the cognitive benefit of these antipsychotic treatments was caused by symptom improvement. The correlations with changes in symptoms were larger at 52 weeks, which suggests that patients who were able to continue treatment to the end of the study may have been more homogeneous and were improving across all symptom domains or that the clinical impact on cognition may require a longer period to fully manifest.
An important consequence of cognitive deficits in psychotic disorders is functional impairment (11) . However, evidence that cognitive improvement with antipsychotic treatment leads to functional change is limited (44) . In this study, patients with early psychosis who demonstrated cognitive improvement at 52 weeks also demonstrated functional benefit in social and occupational domains, which suggests a functional relevance for cognitive improvement. One caveat to this promising conclusion is that given the high dropout rate in this study, these data apply only to the patients who were able to stay in treatment and complete comprehensive assessments for 52 weeks, a group that comprised only 20% of the original sample. In addition, cognitive changes were not predictive of functional change when the analysis controlled for symptom change. Therefore, the functional benefits demonstrated in this study may be associated with cognitive and symptom improvement in patients who remain in treatment for substantial periods of time.
The correlations between cognitive change and change in side effect measures, such as tardive dyskinesia and extrapyramidal symptoms, including akathisia, were small and not statistically significant. Furthermore, patients who required anticholinergic medications or reported sleepiness did not differ from other patients in cognitive composite scores. These data suggest that with atypical antipsychotics, side effects are not an important determinant of cognitive functioning in relatively vulnerable early-psychosis patients with the doses used in this study.
One methodological issue that the data from this study address is the relative sensitivities of the CATIE neurocognitive battery, which was designed specifically for the CATIE project and requires about 90 minutes of testing time, and the BACS, a 35-minute assessment designed to be sensitive to treatment-related cognitive changes in clinical trials. In this study, the correlation between the composite scores for the two batteries was large at each assessment (r=0.84–0.90). The correlation between change in the BACS and change in the CATIE battery was also substantial: 0.70 at week 12 and 0.57 at week 52. The two batteries are similar in their sensitivity to deficits and antipsychotic treatment, association with changes in clinical and functional outcomes, and sensitivity to treatment-related side effects. However, the individual tests of the CATIE battery were slightly more sensitive to treatment differences. These results suggest that the BACS may save time and is equally sensitive to overall treatment differences, although the greater breadth of larger batteries, such as the CATIE battery, might be advantageous for elucidating more specific changes in individual cognitive domains and between treatments.
Footnotes
Received Jan. 27, 2006; revisions received Aug. 29 and Nov. 20, 2006, and Jan. 24, 2007; accepted Jan. 28, 2007. From the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, N.C.; the Department of Psychiatry, University of Illinois at Chicago; the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill; and the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York. Address correspondence and reprint requests to Dr. Keefe, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710; [email protected] (e-mail).
Dr. Keefe reports having received research funding, consulting fees, advisory board payments, or lecture or educational fees from Abbott, Acadia, AstraZeneca, Bristol-Myers Squibb, Cephalon, Dainippon Sumitomo Pharma, Eli Lilly, Forest Labs, Gabriel Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Lundbeck/Solvay/Wyeth, Memory Pharmaceuticals, Merck, Orexigen, Otsuka, Pfizer, Repligen, Saegis, Sanofi/Aventis, and Xenoport; he also receives royalties on the Brief Assessment of Cognition (BACS) and MATRICS battery (BACS symbol coding). Dr. Sweeney was site principal investigator for this study, which was funded by AstraZeneca. Dr. Gu reports no competing interests. Dr. Hamer has served in an advisory, consulting, or data monitoring capacity for or has been involved in a contract agreement between University of North Carolina and the following: Wyeth, Allergan, AstraZeneca, Corcept Pharmaceuticals, Epix Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, SAS Institute, Schwartz, Solvey, and Somerset Pharmaceuticals. He or his wife holds shares of stock from Amgen, Bristol-Myers Squibb, Eli Lilly, Genentech, Proctor & Gamble, and Sepracor. Dr. Perkins has received research funding from AstraZeneca, Bristol-Myers Squibb, Otsuka, Eli Lilly, Janssen, and Pfizer and consulting and educational fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, GlaxoSmithKline, Forest Labs, Pfizer, and Shire. Dr. McEvoy has received research funding or speaking fees from AstraZeneca, Eli Lilly, and Janssen. Dr. Lieberman has received research funding from Acadia, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck, Organon, and Pfizer and holds a patent related to work with Repligen. He has also served without remuneration as a consultant or on advisory boards for AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, and Pfizer.
The Comparison of Atypicals in First Episode of Psychosis research program was coordinated by the University of North Carolina. Funding for this program was provided by AstraZeneca Pharmaceuticals LP (5077IL/0114). The authors acknowledge the assistance of Anusha Bolonna, Ph.D., of PAREXEL MMS, who provided medical writing assistance on the first draft of the manuscript on behalf of AstraZeneca.
This study is registered at www.clinicaltrials.gov under the title “CAFE: Comparison of Atypicals in First Episode of Psychosis” (govIdentifier: NCT00034892, Study ID Numbers: 5077IL/0114). All criteria as stated in the Clinical Trial Registration policy have been met.
References
1.
Harvey PD, Keefe RSE: Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spect 1997; 2:1–11
Sweeney JA, Haas GL, Li S: Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia. Schizophrenia Bull 1992; 18:283–293
Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL: Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 1998; 155:1080–1086
Mohamed S, Paulsen JS, O’Leary D, Arndt S, Andreasen N: Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry 1999; 56:749–754
Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA: Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia. Schizophr Res 2004; 68:49–63
Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA (HGDH Research Group): Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161:985–995
Harvey PD, Rabinowitz J, Eerdekens M, Davidson M: Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005; 162:1888–1895
Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC: Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 2000; 188:518–524
Hoff AL, Harris D, Faustman WO, Beal M, DeVilliers D, Mone RD, Moses JA, Csernansky JG: A neuropsychological study of early onset schizophrenia. Schizophr Res 1996; 20:21–28
Buchanan RW, Holstein C, Breier A: The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36:717–725
Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD; the Canadian Collaborative Group for Research in Schizophrenia: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000; 57:249–258
Purdon SE, Malla A, Labelle A, Lit W: Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26:137–149
Harvey PD, Keefe RSE: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158:176–184
Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159:1018–1028
Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin RK, Miller AL: Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002; 53:239–248
Woodward ND, Purdon SE, Meltzer HY, Zald DH: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8:457–472
Keefe RSE, Silva SG, Perkins DO, Lieberman JA: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25:201–222
McEvoy JP, Lieberman JA, Perkins D, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD: Effects of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind, clinical trial. Am J Psychiatry 2007; 164:1061–1071
Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L: The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004; 68:283–297
Keefe RSE, Poe M, Walker TM, Harvey PD: The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. J Clin Exp Neuropsychol 2006; 28:260–269
Heinrichs DW, Hanlon TE, Carpenter WT Jr: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388–398
Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534–537
Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A (HGGN Study Group): One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006; 81:1–15
Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; the CATIE Investigators and the Neurocognitive Working Group: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry (in press)
Kapur S, Seeman P: Does fast dissociation from the dopamine D 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001; 158:360–369
Lee MA, Jayathilake K, Meltzer HY: A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 1999; 37:1–11
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
If the address matches an existing account you will receive an email with instructions to retrieve your username
Create a new account
Change Password
Password Changed Successfully
Your password has been changed
Login
Reset password
Can't sign in? Forgot your password?
Enter your email address below and we will send you the reset instructions
If the address matches an existing account you will receive an email with instructions to reset your password.
Change Password
Congrats!
Your Phone has been verified
×
As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
